Fatty liver disease (MASLD/MASH) trials in Netherlands

In Netherlands 15 Also abroad 367

15 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Where
Amsterdam, Dordrecht, Leiden, Nijmegen, Rotterdam, Tilburg, Utrecht
Age
18 years and over
People
1,800 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06632444 · EU 2024-513739-25-00
Phase 3Taking people
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Where
Dordrecht, Leiden, Nijmegen, Rotterdam, Tilburg, Uden, Utrecht
Age
18 years and over
People
1,590 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT06632457 · EU 2024-513741-36-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Where
Amsterdam, Rotterdam, Utrecht
Age
18 years to 80 years
People
1,350 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06318169 · EU 2023-509912-27-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Where
Amsterdam, Rotterdam, Tilburg, Utrecht
Age
18 years to 75 years
People
1,800 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06419374 · EU 2023-510395-31-00
Phase 3Not yet taking people in Netherlands
A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)
Where
Amsterdam, Rotterdam, Uden
Age
18 years and over
People
382 worldwide
Run by
Glaxosmithkline Research & Development Limited
See details and how to join2026-525755-82-00 · EU 2026-525755-82-00
Phase 3Not yet taking people in Netherlands
A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)
Where
Amsterdam, Rotterdam, Uden
Age
18 years and over
People
69 worldwide
Run by
Glaxosmithkline Research & Development Limited
See details and how to join2026-525757-37-00 · EU 2026-525757-37-00
Phase 3Taking people
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Where
Amsterdam, Nijmegen, Rotterdam, 's-Hertogenbosch, Utrecht, Zwolle
Age
18 years and over
People
4,500 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07165028 · EU 2025-522674-36-00
Phase 3Taking people
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
Where
Amsterdam, Rotterdam, Uden
Age
18 years to 75 years
People
1,250 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07221188 · EU 2025-523674-16-00
Phase 4Enrolling by invitation
Effect of an Early Time Restricted Eating Mediterranean Diet Compared to Naltrexone/Bupropion on Liver Fibrosis in People With Cardiometabolic Risk Factors in a Hospital Outpatient Clinic (MEDFAST-study)
Where
Rotterdam
Age
18 years to 75 years
People
70
Run by
Carmen Dietvorst
See details and how to joinNCT06845345 · EU 2024-519774-40-00
No phaseTaking people
Hepatic Gene Response to Intravenous Glucose in Obese Patients With and Without MASLD Undergoing Bariatric Surgery
Where
Amsterdam
Age
35 years to 65 years
People
40
Run by
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
See details and how to joinNCT07326865
No phaseTaking people
Global Research Initiative for Patients Screening on MASH
Where
Amsterdam, Rotterdam
Age
18 years to 75 years
People
10,000 worldwide
Run by
Julius Clinical
See details and how to joinNCT05651724
No phaseTaking people
Effect of Timed-Restricted Eating on Metabolic Health
Where
Amsterdam
Age
50 years to 75 years
People
30
Run by
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
See details and how to joinNCT06061042
No phaseTaking people
The European NAFLD Registry
Where
Amsterdam
Age
18 years to 100 years
People
10,000 worldwide
Run by
Newcastle University
See details and how to joinNCT04442334
No phaseTaking people
European Paediatric Non-Alcoholic Fatty Liver Disease Registry (EU-PNAFLD)
Where
Maastricht
Age
Up to 18 years
People
2,000 worldwide
Run by
Cambridge University Hospitals NHS Foundation Trust
See details and how to joinNCT04190849
No phaseTaking people
Prospective Cohort, With Biobanking, of Patients With Nonalcoholic Fatty Liver Disease
Where
Maastricht
Age
18 years to 65 years
People
500
Run by
Maastricht University Medical Center
See details and how to joinNCT02422238